Alpelisib + Placebo
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphatic Malformations
Conditions
Lymphatic Malformations
Trial Timeline
Nov 24, 2023 → May 2, 2033
NCT ID
NCT05948943About Alpelisib + Placebo
Alpelisib + Placebo is a phase 2/3 stage product being developed by Novartis for Lymphatic Malformations. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05948943. Target conditions include Lymphatic Malformations.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05948943 | Phase 2/3 | Recruiting |
| NCT04589650 | Phase 2 | Active |
Competing Products
5 competing products in Lymphatic Malformations
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AWZ1066S + Placebo | Eisai | Phase 1 | 33 |
| Remdesivir | Gilead Sciences | Phase 2 | 51 |
| TARA-002 | Protara Therapeutics | Phase 2 | 44 |
| SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran | Arcturus Therapeutics | Phase 2 | 44 |
| BIVV003 + ST-400 | Sangamo Therapeutics | Pre-clinical | 15 |